## **U.S. EPA: Fragrance Technical Expert Meeting**

January 30-31, 2024
Room 1153 ("The Map Room")
U.S. EPA William Jefferson Clinton East Building
1201 Constitution Ave.
Washington, D.C. 20460

## Day One - Quantitative Evaluation of Dermal Sensitization

	)
08:30	Welcome (Elissa Reaves, EPA)
08:45	Meeting Expectations & Themes (Shari Barash and Anna Lowit, EPA)
09:00	Session 1: Setting the Stage - Identifying Hazard and Risk for the Dermal Sensitization Endpoint (Louis Scarano, EPA)
09:30	Session 2: The Skin Allergy Risk Assessment (SARA) Model as a Quantitative Dermal Sensitization Method and its incorporation into the Integrated Chemical Environment (ICE) Platform (Emily Reinke, NICEATM and Joe Reynolds, Unilever)
10:15	BREAK
10:30	Session 3: Stakeholder Presentations (5 mins. each)  Anna van der Zalm (PETA)*  Anne Marie Api (RIFM)*  John Piper (LANXESS, FCA)*  Isabelle Lee (RIFM)*  Shashikiran Donthamsetty (IFF, FCA)*  Malick Diop (MANE Flavor & Fragrance Manufacturer, FCA)*  Kristie Sullivan (IIVS)*  Vanessa Rocha (Givaudan) and Nicholas Georges (FSAC)*
12:00	LUNCH
01:00	Session 3 (continued): Discussion on SARA/ICE
	There are several methods available to identify a point of departure (POD) to quantify hazard for risk assessment purposes for the dermal sensitization endpoint. Please provide individual input on EPA's proposal to use the SARA/ICE model for this purpose. Considerations may include:
	<ol> <li>Are there other methods/models that have been (or are being) evaluated by the OECD for the same purpose?</li> <li>What are the strengths and limitations of the SARA/ICE model?</li> <li>The SARA/ICE model can use the following information: in vitro inputs (DPRA, kDPRA, KeratinoSensTM, h-CLAT, USensTM) and in vivo inputs (HPPT, LLNA). Given this list, which of these data already exist for fragrance chemicals?</li> <li>What resources or training will be needed to make the SARA/ICE model accessible and implementable?</li> </ol>
02:30	BREAK
03:00	Next Steps & General Discussion
4:30	Adjourn
	•

## **U.S. EPA: Fragrance Technical Expert Meeting**

January 30-31, 2024
Room 1153 ("The Map Room")
U.S. EPA William Jefferson Clinton East Building
1201 Constitution Ave.
Washington, D.C. 20460

## Day Two - Understanding Biodegradation & Evaluating Environmental Hazard

Day Iwo - Olio	erstanding blodegradation & Evaluating Environmental Hazard
08:30	Welcome (Elissa Reaves, EPA)
08:45	Meeting Expectations & Themes (Shari Barash and Anna Lowit, EPA)
09:00	Session 1: Setting the Stage - Evaluating Environmental Fate and Hazard of New Chemicals Under TSCA (Jeffrey Gallagher, EPA)
09:30	Session 2: Understanding Biodegradation of Fragrances (Danielle Johnson, EPA)  Stakeholder Presentations (5 mins. each)  • Aurelia Lapczynski (RIFM)*  • Jared Bozich (IFF, FCA)*  • Sylvia Gimeno (Firmenich)*
10:15	BREAK
10:30	Session 2 (continued): Discussion
	Please provide individual input on the availability of biodegradation information (e.g., methods, tools and models, and results) that are relevant to the fragrance industry and could be used for the purposes of read-across to better inform our models.  1. Are you aware of any specific fate and transport models to predict the biodegradation of fragrances?  2. Have you identified any OECD, EPA, or other test guidelines that are suitable for evaluating the biodegradation of fragrances?
12:00	LUNCH
1:00	Session 3: Evaluating Chronic Aquatic Toxicity with Fragrances (Nicholas Turner, EPA) Stakeholder Presentations (5 mins. each)
	<ul> <li>Gordon Sanders (Givaudan)*</li> <li>Aurelia Lapczynski (RIFM)*</li> <li>Ming Fan (P&amp;G, FCA)*</li> <li>Chris Fassbender (PETA)*</li> <li>William Eckel (EPA/OPP) – not external stakeholder</li> <li>Kristin Schirmir (Eawag)*</li> </ul>
1:45	BREAK
2:15	Session 3 (continued): Discussion
	Please provide individual input on the availability of chronic aquatic toxicity information (fish and aquatic invertebrates), methods (including New Approach Methods, or NAMs), and results that are relevant to the fragrance industry and could be used for the purposes of read-across to better inform our models and/or acute to chronic ratios (ACRs).
3:30	Next Steps & General Discussion

Adjourn

4:30